NCT06938854进行中（未招募）不适用
Prospective, Multi-center, Single-arm Investigational Study of SWM-831 to Treat Moderate and Severely Calcified Femoropopliteal Arteries
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 81
- 试验地点
- 11
- 主要终点
- Percentage of Subjects with Procedural Success
研究概览
简要总结
Disrupt PAD Japan is a prospective, multi-center, single-arm study of SWM-831 to treat moderate and severely calcified femoropopliteal arteries, prior to DCB or stenting.
详细描述
Up to 60 subjects at up to 10 sites in Japan will be enrolled in the femoropopliteal clinical study with moderate and severely calcified femoropopliteal artery disease presenting with Rutherford Category 2 - 5 of the target limb.
Two additional cohorts [Iliac and BTK (Below-the-Knee)] will enroll a minimum of 10 and a maximum of 15 subjects each with moderate and severely calcified iliac disease with a Rutherford Category (RC) 2 - 5 and a minimum of 10 and a maximum of 15 subjects with moderate and severely calcified BTK lesions with a Rutherford Category (RC) 2 - 5 will be enrolled and followed through 12 months.
The estimated study duration for these cohorts is approximately 24 months. Study subjects will be followed through discharge, 30 days, 6, and 12 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •General Inclusion Criteria:
- •Subjects are required to meet all of the following inclusion criteria in order to be enrolled in the clinical study:
- •1. Subject is able and willing to comply with all assessments in the study.
- •2. Subject or subject's legal representative has been informed of the nature of the study, agrees to participate and has signed the approved consent form.
- •3. Age of subject is ≥ 18. Note: If a subject is under 20 years, voluntary agreement shall be obtained from both the subject and the subject's representative or legal guardian using the written consent form.
- •4. Rutherford Clinical Category 2, 3, 4, or 5 of the target limb.
- •5. Estimated life expectancy \> 1 year.
- •Angiographic Inclusion Criteria:
- •Subjects are required to meet all of the following inclusion criteria in order to be enrolled in the clinical study. For lesion characteristics, each target lesion must meet eligibility.
- •1. One target lesion that is located in a native, de novo superficial femoral artery (SFA) or popliteal artery (popliteal artery extends to and ends proximal to the ostium of the anterior tibial artery). \ 2. Target lesion reference vessel diameter (RVD) is between 4.0 mm and 8.0 mm by investigator visual estimate. \ 3. Target lesion with ≥ 70% stenosis by investigator visual estimate.
- •4. Target lesion length is ≤ 200 mm by investigator visual estimate. Target lesion can be all or part of the 200 mm treated zone.
- •5. Subject has at least one patent tibial vessel on the target limb with runoff to the foot, defined as no stenosis ≥ 50%.
- •6. Calcification is determined to be grade 2 - 4 (unilateral calcification ≥ 5 cm, bilateral wall calcification \< 5 cm, and bilateral calcification ≥ 5 cm, respectively), as defined by PACSS (Peripheral Artery Calcification Scoring System). \ Angiographic Inclusion Criteria specific to Iliac Arteries
- •1. Target lesion located in the native, de novo common or external iliac artery.
- •2. Target lesion reference vessel diameter (RVD) is between 5.0 mm and 10.0 mm by investigator visual estimate.
- •3. Evidence of PACSS calcification grade 2 - 4 and non-dilatable lesion indicating presence of calcium.
- •Note: Non-dilatable lesion requires attempted treatment with PTA during the index procedure with residual stenosis ≥ 50% and no serious angiographic complication.
- •Angiographic Inclusion Criteria specific to BTK Arteries
- •1. Target lesion from the native, de novo distal segment of the popliteal artery to the ankle joint.
- •2. Target lesion reference vessel diameter (RVD) is between 2.0 mm and 4.0 mm by investigator visual estimate.
- •3. Evidence of PACSS calcification grade 2 - 4 and non-dilatable lesion indicating presence of calcium.
- •Note: Non-dilatable lesion requires attempted treatment with PTA during the index procedure with residual stenosis ≥ 50% and no serious angiographic complication.
排除标准
- •Subjects who meet any of the following exclusion criteria may not be enrolled in the study:
- •1. Rutherford Clinical Category 0, 1 and 6.
- •2. Subject has known or suspected active infection evidenced by WBC \> 14.0 (14000/mm3) within 14 days prior to index procedure.
- •3. Previous or planned target limb major amputation (above the ankle).
- •4. History of prior endovascular or surgical procedure on the index limb within the past 30 days or planned within 30 days of the index procedure.
- •Note: Inflow treatment of non-target lesions is allowed provided successful treatment.
- •5. Subject in whom antiplatelet or anticoagulant therapy is contraindicated.
- •6. Subject has known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated.
- •7. Subject has known allergy to urethane, nylon, or silicone.
- •8. History of myocardial infarction within 60 days prior to enrollment.
- •9. History of stroke within 60 days prior to enrollment.
- •10. History of thrombolytic therapy within two weeks prior to enrollment.
- •11. Subject has acute or chronic renal disease with creatinine \> 2.5 mg/dL, unless on dialysis.
- •12. Subject is pregnant or nursing.
- •13. Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint.
- •14. Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.
- •15. The use of specialty balloons, re-entry or atherectomy devices.
- •16. Active COVID-19 or previously diagnosed COVID-19 with sequelae that could confound endpoint assessments.
- •17. Subject has an anticipated life span of less than one (1) year.
- •General Exclusion Criteria specific to BTK Arteries
- •1. Subjects with osteomyelitis or deep soft tissue infection in the target limb.
- •2. Acute limb ischemia (of either leg).
- •3. Occlusion of all the inframalleolar outflow arteries/vessels (i.e., desert foot) in the target limb.
- •Angiographic Exclusion Criteria
- •Subjects who meet any of the following exclusion criteria may not be enrolled in the study:
- •1. In-stent restenosis within 10 mm of the target lesion.
- •2. Lesion within 10 mm of the ostium of the SFA or within 10 mm proximal to the anterior tibial artery ostium. \ 3. Evidence of aneurysm or thrombus in target vessel.
- •4. No calcium or mild calcium in the target lesion by PACSS.
- •5. Target lesion within native or synthetic vessel grafts.
- •6. Subject has significant stenosis (≥ 50% stenosis) or occlusion of inflow tract before target treatment zone (e.g., iliac or common femoral) not successfully treated.
- •7. Failure to successfully treat significant distal non-target lesions, if treated prior to target lesion. Successful treatment is defined as obtaining \< 50% residual stenosis with no serious angiographic complications (e.g., embolism).
- •8. Failure to successfully cross the guidewire across the target lesion; successful crossing defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations.
- •Angiographic Exclusion Criteria specific to Iliac Arteries
- •1.Target lesion with any aorta involvement.
- •Angiographic Exclusion Criteria specific to BTK Arteries
- •1. Failure to treat clinically significant inflow lesions in the ipsilateral iliac, femoral, or popliteal arteries with \< 30% residual stenosis, and no serious angiographic complications (e.g., embolism).
- •2. Treatment of vessels below the ankle joint.
结局指标
主要结局
Percentage of Subjects with Procedural Success
时间窗: Day 0
Primary Endpoint for Femoropopliteal: Procedural success is defined as residual stenosis \< 50% without ≥ grade D dissections, prior to Drug-Coated Balloon (DCB) or stenting for the treated target lesion (core lab assessed)
次要结局
- Residual stenosis < 50% without ≥ grade D dissections(Day 0)
- Rate of ≥ grade D dissections, perforation, distal embolization, slow flow or acute vessel closure(Day 0)
- Residual stenosis < 30% without ≥ grade D dissections(Day 0)
- Number of participants with freedom from clinically-driven target lesion revascularization (CD-TLR) CEC adjudicated and freedom from restenosis as determined by duplex-derived peak systolic velocity ratio (PSVR) ≤ 2.4, assessed by the DUS core lab.(At 6 months and 12 months post-procedure)
- Number of participants with Major Adverse Event(At 30 days, 6 months and 12 months post-procedure)
- Number of participants with change in Ankle brachial index (ABI) or Toe brachial index (TBI)(At 30 days, 6 months, and 12 months post-procedure)
- Number of participants with change in Rutherford Category(At 30 days, 6 months, and 12 months post-procedure)
- Rate of ≥ grade D dissections, perforation, distal embolization, slow flow or acute vessel closure(Day 0)
- Residual stenosis < 50% without ≥ grade D dissections(Day 0)
- Residual stenosis < 30% without ≥ grade D dissections(Day 0)
- Number of participants with freedom from clinically-driven target lesion revascularization (CD-TLR) CEC adjudicated and freedom from restenosis as determined by duplex-derived peak systolic velocity ratio (PSVR) ≤ 2.4, assessed by the DUS core lab.(At 6 months and 12 months post-procedure)
- Number of participants with Major Adverse Event(At 30 days, 6 months and 12 months post-procedure)
- Number of participants with change in Ankle brachial index (ABI) or Toe brachial index (TBI)(At 30 days, 6 months, and 12 months post-procedure)
- Number of participants with change in Rutherford Category(At 30 days, 6 months, and 12 months post-procedure)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
1 期
Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055Solid TumorsAdvanced Solid MalignanciesCancerNCT00973076AstraZeneca19
已完成
4 期
Safety and Efficacy of Insulin Aspart in Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01649570Novo Nordisk A/S123
已完成
1 期
Phase I Study of GW856553 (Losmapimod)Acute Coronary SyndromeNCT01648192GlaxoSmithKline20
已完成
1 期
Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.NeoplasmsMetastatic CancerBreast CancerNCT01003158AstraZeneca17
已完成
3 期
Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis SuppurativaHidradenitis SuppurativaNCT02904902AbbVie15